Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel - PubMed (original) (raw)
Review
Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel
MaryAnn Foote. Biotechnol Annu Rev. 2007.
Abstract
Nanotechnology refers to the use of very small pieces of matter, typically < or =200 nm in diameter. Nanoparticle albumin-bound (nab) paclitaxel, a soluble form of the cytotoxin paclitaxel that has demonstrated utility in the setting of cancer chemotherapy, is produced by nab technology using the protein albumin. nab-Paclitaxel targets tumors, enhances tumor penetration by the novel mechanism of albumin receptor-mediated (gp60) endothelial transcytosis, and avoids the use of surfactants and solvents such as Cremophor and Tween. nab-Paclitaxel minimizes the toxicities associated with Cremophor and eliminates the need for premedication for hypersensitivity reactions caused by Cremophor. The albumin coating that surrounds the active drug assists in the transport of the nanoparticles to the interior of the tumor cell that preferentially takes in albumin as a nutrient through the gp60 pathway. In nonclinical studies, nab-paclitaxel achieved higher intratumoral concentrations compared with solvent-based paclitaxel and increased the bioavailability of paclitaxel by eliminating the entrapment of paclitaxel in the plasma. Compared with solvent-based paclitaxel, at equitoxic doses, the nab-paclitaxel produced more complete regressions, longer time to recurrence, longer doubling times, and prolonged survival. nab-Paclitaxel has been shown to have superior efficacy compared with solvent-based paclitaxel without the need for premedication in clinical trials of patients with advanced solid tumors. nab-Paclitaxel has been effective in patients for whom previous chemotherapy has not been helpful. nab Technology has the potential to be applied to other insoluble drugs.
Similar articles
- Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ, Soon-Shiong P, Desai N. Hawkins MJ, et al. Adv Drug Deliv Rev. 2008 May 22;60(8):876-85. doi: 10.1016/j.addr.2007.08.044. Epub 2008 Feb 7. Adv Drug Deliv Rev. 2008. PMID: 18423779 Review. - Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Desai N, et al. Clin Cancer Res. 2006 Feb 15;12(4):1317-24. doi: 10.1158/1078-0432.CCR-05-1634. Clin Cancer Res. 2006. PMID: 16489089 - Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
Stinchcombe TE. Stinchcombe TE. Nanomedicine (Lond). 2007 Aug;2(4):415-23. doi: 10.2217/17435889.2.4.415. Nanomedicine (Lond). 2007. PMID: 17716129 Review. - 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz TA, Milas L, Mason KA. Wiedenmann N, et al. Clin Cancer Res. 2007 Mar 15;13(6):1868-74. doi: 10.1158/1078-0432.CCR-06-2534. Clin Cancer Res. 2007. PMID: 17363543 - Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L. Lluch A, et al. Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Crit Rev Oncol Hematol. 2014. PMID: 24071503 Review.
Cited by
- Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.
Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Aggarwal P, et al. Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37. doi: 10.1016/j.addr.2009.03.009. Epub 2009 Apr 17. Adv Drug Deliv Rev. 2009. PMID: 19376175 Free PMC article. Review. - Nanopharmaceuticals (part 1): products on the market.
Weissig V, Pettinger TK, Murdock N. Weissig V, et al. Int J Nanomedicine. 2014 Sep 15;9:4357-73. doi: 10.2147/IJN.S46900. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25258527 Free PMC article. Review. - Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo.
Strüh CM, Jäger S, Kersten A, Schempp CM, Scheffler A, Martin SF. Strüh CM, et al. PLoS One. 2013 Apr 17;8(4):e62168. doi: 10.1371/journal.pone.0062168. Print 2013. PLoS One. 2013. PMID: 23614029 Free PMC article. - Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
Li F, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai MP, Yuan H, Sun D. Li F, et al. Mol Pharm. 2018 Oct 1;15(10):4505-4516. doi: 10.1021/acs.molpharmaceut.8b00527. Epub 2018 Sep 21. Mol Pharm. 2018. PMID: 30180593 Free PMC article. - Controlled Delivery of Paclitaxel via Stable Synthetic Protein Nanoparticles.
Mauser A, Waibel I, Banerjee K, Mujeeb AA, Gan J, Lee S, Brown W, Lang N, Gregory J, Raymond J, Franzeb M, Schwendeman A, Castro MG, Lahann J. Mauser A, et al. Adv Ther (Weinh). 2024 Nov;7(11):2400208. doi: 10.1002/adtp.202400208. Epub 2024 Jun 27. Adv Ther (Weinh). 2024. PMID: 39575154 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources